株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨粗鬆症:パイプライン製品の分析

Osteoporosis - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 232788
出版日 ページ情報 英文 251 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.43円で換算しております。
Back to Top
骨粗鬆症:パイプライン製品の分析 Osteoporosis - Pipeline Review, H1 2018
出版日: 2018年04月30日 ページ情報: 英文 251 Pages
概要

骨粗鬆症は、骨量の減少により骨の強度が弱まり骨折しやすくなる疾患です。加齢、性別、低体重、性ホルモンの不足または閉経、喫煙、ある種の薬剤による発症のリスクがあります。症状は脊椎の破損や圧迫骨折による腰痛、身長の低下、前屈姿勢、容易な骨折などであり、予防または治療として、カルシウム、ビタミンDの摂取、運動、治療薬による治療が挙げられます。

当レポートでは、骨粗鬆症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

骨粗鬆症 - 概要

骨粗鬆症 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

骨粗鬆症 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

骨粗鬆症の治療薬開発に従事している企業

  • Addex Therapeutics Ltd
  • Alize Pharma SAS
  • Alvogen Korea Co Ltd
  • Amgen Inc
  • Amura Holdings Ltd
  • BiologicsMD Inc
  • Bone Biologics Corp
  • Bristol-Myers Squibb Company
  • Cellmid Ltd
  • ChoDang Pharm Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corium International Inc
  • Critical Pharmaceuticals Ltd
  • 第一三共
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzo Biochem Inc
  • F. Hoffmann-La Roche Ltd
  • Gador SA
  • GL Pharm Tech Corp
  • Glide Pharmaceutical Technologies Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Haoma Medica Ltd
  • Immunovo BV
  • Immunwork Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Kaken Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • Ligand Pharmaceuticals Inc
  • Lotus Pharmaceutical Co Ltd
  • Lupin Ltd
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • NIBEC
  • Omeros Corp
  • Oncobiologics Inc
  • Osteologix Holdings Plc
  • Paras Biopharmaceuticals Finland Oy
  • Pfenex Inc
  • PhytoHealth Corp
  • R Pharm
  • Ribomic Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shin Poong PharmCo Ltd
  • Sinil Pharmaceutical Co Ltd
  • Stelis Biopharma Pvt Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Terpenoid Therapeutics Inc
  • TSH Biopharm Corporation Ltd
  • Uni-Bio Science Group Ltd
  • Viking Therapeutics Inc
  • Wroclawskie Centrum Badan EIT+ Sp z oo
  • Yooyoung Pharm Co Ltd
  • Zydus Cadila Healthcare Ltd

薬剤プロファイル

骨粗鬆症 - 休止中のプロジェクト

骨粗鬆症 - 開発が中止された製品

骨粗鬆症 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

目次
Product Code: GMDHC10379IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2018, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 6, 4, 16, 1, 56, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 14 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Osteoporosis - Overview
  • Osteoporosis - Therapeutics Development
  • Osteoporosis - Therapeutics Assessment
  • Osteoporosis - Companies Involved in Therapeutics Development
  • Osteoporosis - Drug Profiles
  • Osteoporosis - Dormant Projects
  • Osteoporosis - Discontinued Products
  • Osteoporosis - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Osteoporosis, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 7: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 8: Products under Development by Companies, H1 2018
  • Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 14: Table 15Products under Development by Universities/Institutes, H1 2018
  • Table 16: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
  • Table 17: Number of Products by Stage and Target, H1 2018
  • Table 18: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Table 19: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 20: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Table 21: Number of Products by Stage and Route of Administration, H1 2018
  • Table 22: Number of Products by Stage and Molecule Type, H1 2018
  • Table 23: Osteoporosis - Pipeline by Abreos Biosciences Inc, H1 2018
  • Table 24: Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H1 2018
  • Table 25: Osteoporosis - Pipeline by Amgen Inc, H1 2018
  • Table 26: Osteoporosis - Pipeline by Asahi Kasei Corp, H1 2018
  • Table 27: Osteoporosis - Pipeline by BiologicsMD Inc, H1 2018
  • Table 28: Osteoporosis - Pipeline by Bone Biologics Corp, H1 2018
  • Table 29: Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Table 30: Osteoporosis - Pipeline by Cadila Healthcare Ltd, H1 2018
  • Table 31: Osteoporosis - Pipeline by Cellmid Ltd, H1 2018
  • Table 32: Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2018
  • Table 33: Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
  • Table 34: Osteoporosis - Pipeline by Corium International Inc, H1 2018
  • Table 35: Osteoporosis - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
  • Table 36: Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, H1 2018
  • Table 37: Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2018
  • Table 38: Osteoporosis - Pipeline by Eli Lilly and Co, H1 2018
  • Table 39: Osteoporosis - Pipeline by EndoCeutics Inc, H1 2018
  • Table 40: Osteoporosis - Pipeline by Entera Bio Ltd, H1 2018
  • Table 41: Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2018
  • Table 42: Osteoporosis - Pipeline by Enzene Biosciences Ltd, H1 2018
  • Table 43: Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2018
  • Table 44: Osteoporosis - Pipeline by Evgen Pharma Plc, H1 2018
  • Table 45: Osteoporosis - Pipeline by Gador SA, H1 2018
  • Table 46: Osteoporosis - Pipeline by GL Pharm Tech Corp, H1 2018
  • Table 47: Osteoporosis - Pipeline by GlycoNex Inc, H1 2018
  • Table 48: Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
  • Table 49: Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2018
  • Table 50: Osteoporosis - Pipeline by Huons Global Co Ltd, H1 2018
  • Table 51: Osteoporosis - Pipeline by Immunovo BV, H1 2018
  • Table 52: Osteoporosis - Pipeline by Immunwork Inc, H1 2018
  • Table 53: Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2018
  • Table 54: Osteoporosis - Pipeline by Ipsen SA, H1 2018
  • Table 55: Osteoporosis - Pipeline by JHL Biotech Inc, H1 2018
  • Table 56: Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018
  • Table 57: Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2018
  • Table 58: Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2018
  • Table 59: Osteoporosis - Pipeline by Lupin Ltd, H1 2018
  • Table 60: Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2018
  • Table 61: Osteoporosis - Pipeline by mAbxience SA, H1 2018
  • Table 62: Osteoporosis - Pipeline by Merck & Co Inc, H1 2018
  • Table 63: Osteoporosis - Pipeline by Millendo Therapeutics Inc, H1 2018
  • Table 64: Osteoporosis - Pipeline by NIBEC, H1 2018
  • Table 65: Osteoporosis - Pipeline by Omeros Corp, H1 2018
  • Table 66: Osteoporosis - Pipeline by Oncobiologics Inc, H1 2018
  • Table 67: Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018
  • Table 68: Osteoporosis - Pipeline by Pfenex Inc, H1 2018
  • Table 69: Osteoporosis - Pipeline by PhytoHealth Corp, H1 2018
  • Table 70: Osteoporosis - Pipeline by R Pharm, H1 2018
  • Table 71: Osteoporosis - Pipeline by Ribomic Inc, H1 2018
  • Table 72: Osteoporosis - Pipeline by Richter Gedeon Nyrt, H1 2018
  • Table 73: Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
  • Table 74: Osteoporosis - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2018
  • Table 75: Osteoporosis - Pipeline by Shin Poong PharmCo Ltd, H1 2018
  • Table 76: Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2018
  • Table 77: Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2018
  • Table 78: Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2018
  • Table 79: Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2018
  • Table 80: Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2018
  • Table 81: Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2018
  • Table 82: Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2018
  • Table 83: Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2018
  • Table 84: Osteoporosis - Dormant Projects, H1 2018
  • Table 85: Osteoporosis - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Table 86: Osteoporosis - Dormant Projects, H1 2018 (Contd..2), H1 2018
  • Table 87: Osteoporosis - Dormant Projects, H1 2018 (Contd..3), H1 2018
  • Table 88: Osteoporosis - Dormant Projects, H1 2018 (Contd..4), H1 2018
  • Table 89: Osteoporosis - Dormant Projects, H1 2018 (Contd..5), H1 2018
  • Table 90: Osteoporosis - Dormant Projects, H1 2018 (Contd..6), H1 2018
  • Table 91: Osteoporosis - Dormant Projects, H1 2018 (Contd..7), H1 2018
  • Table 92: Osteoporosis - Discontinued Products, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Osteoporosis, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Figure 4: Number of Products by Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 6: Number of Products by Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Stage and Mechanism of Actions, H1 2018
  • Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top